Clovis Oncology News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

17.09.20	New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline (Businesswire)
10.09.20	Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting (Businesswire)
09.09.20	Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020 (Businesswire)
08.09.20	Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference (Businesswire)
27.08.20	Pre-market Movers In Healthcare Sector: EYPT, CLVS, ABT, VBIV, LPCN... (RTTNews)
27.08.20	FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) (Businesswire)
17.08.20	Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations (Businesswire)
06.08.20	Clovis Oncology Announces Second Quarter 2020 Operating Results (Businesswire)
05.08.20	Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers (Businesswire)
05.08.20	Ausblick: Clovis Oncology präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
23.07.20	Clovis Oncology to Announce Second Quarter 2020 Financial Results and Host Webcast Conference Call on August 6 (Businesswire)
17.06.20	Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020 (Businesswire)
10.06.20	Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial, a Phase 3 Maintenance Treatment Study in Front-line, Newly-Diagnosed Advanced Ovarian Cancer (Businesswire)
31.05.20	Mai 2020: Die Expertenmeinungen zur Clovis Oncology-Aktie (finanzen.net)
21.05.20	Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program (Businesswire)
19.05.20	Clovis Oncology Announces Pricing of Public Offering of Common Stock (Businesswire)
18.05.20	Clovis Oncology Announces Proposed Offering of Common Stock (Businesswire)
05.05.20	Clovis Oncology Announces First Quarter 2020 Operating Results (Businesswire)
04.05.20	Ausblick: Clovis Oncology legt Quartalsergebnis vor (finanzen.net)
30.04.20	Experten sehen bei Clovis Oncology-Aktie weniger Potenzial (finanzen.net)
29.04.20	Clovis Oncology to Present at the Bank of America Health Care Conference 2020 (Businesswire)
28.04.20	Biotech Stocks Facing FDA Decision In May 2020 (RTTNews)
21.04.20	Clovis Oncology to Announce First Quarter 2020 Financial Results and Host Webcast Conference Call on May 5 (Businesswire)
14.04.20	Clovis Oncology Announces Debt Exchange Transaction (Businesswire)
03.03.20	Clovis Oncology to Present at the Barclays Global Healthcare Conference (Businesswire)
02.03.20	Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Spain (Businesswire)
24.02.20	Clovis Oncology Announces 2019 Operating Results (Businesswire)
23.02.20	Ausblick: Clovis Oncology zieht Bilanz zum abgelaufenen Quartal (finanzen.net)
13.02.20	Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24 (Businesswire)
11.02.20	Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference (Businesswire)
03.02.20	Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France (Businesswire)
15.01.20	Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer (Businesswire)
09.01.20	FDA Nod For MRK, All Eyes On AGTC, ACTION Boosts APLT (RTTNews)
07.01.20	Clovis Oncology Announces Debt Refinancing Transaction (Businesswire)
07.01.20	Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019 (Businesswire)
16.12.19	Initial Clinical Experience Reported from FAP-2286 Named-Patient Use at ICPO Symposium (Businesswire)
14.12.19	Are These Biotech Companies Buyout Candidates? Deal Or No Deal? (RTTNews)
14.11.19	Clovis Oncology kündigt Erstattung für Rubraca®-Tabletten (Rucaparib) für Frauen mit rezidivierendem Eierstockkrebs in Italien an (Businesswire)
14.11.19	Today's Top 5 Gainers In Healthcare Sector (IDYA, ELMD, CLBS…) (RTTNews)
13.11.19	Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy (Businesswire)
07.11.19	Clovis Oncology Announces Third Quarter 2019 Operating Results (Businesswire)
29.10.19	Top 6 Gainers In Healthcare Sector Today (CRVS, CLVS, TGTX…) (RTTNews)
22.10.19	Clovis Oncology to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 7 (Businesswire)
18.10.19	Today's Top 5 Gainers In Healthcare Sector (HEPA, ENDP, CLVS...) (RTTNews)
11.10.19	Clovis Oncology Announces Rubraca®? (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund (Businesswire)
23.09.19	Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals (Businesswire)
12.09.19	Clovis Oncology to Highlight Expanded Data from Rubraca® (rucaparib) TRITON and ARIEL Clinical Programs in Prostate and Ovarian Cancers at the ESMO Congress 2019 (Businesswire)
28.08.19	Clovis Oncology to Present at 2019 Wells Fargo Healthcare Conference (Businesswire)
22.08.19	Clovis Oncology Announces Exercise by Initial Purchasers of Their Option to Purchase an Additional $13.0 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024 (Businesswire)
09.08.19	Clovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’406.50	1.48 %	K V
Swiss Life Hldg	764.20	1.16 %	K V
Kuehne+Nagel Int	203.80	1.14 %	K V
Logitech Intl	91.02	0.91 %	K V
ABB	50.08	0.81 %	K V
Nestle	77.36	-0.18 %	K V
Swisscom	526.00	-0.19 %	K V
UBS Group	30.31	-0.36 %	K V
Givaudan	3’828.00	-0.57 %	K V
Alcon	81.70	-0.73 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Clovis Oncology Inc.

Aktien Top/Flop

Meistgelesene Nachrichten